SCHEMBL318609

SCHEMBL318609

O=C(O)c1ccc(F)c(Br)c1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.45
CES1 P23141 2/20 0.45
KDM4E B2RXH2 3/20 0.42
ASPH Q12797 1/20 0.42
KDM8 Q8N371 1/20 0.42
CYP1A2 P05177 1/20 0.42
ALB P02768 2/20 0.41
DGAT1 O75907 1/20 0.38
MAP2K1 Q02750 2/20 0.38
MAP2K2 P36507 1/20 0.38
TSHR P16473 3/20 0.38
CASP1 P29466 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALDH1A1 P00352 3/20 0.37
ALOX15 P16050 1/20 0.37
ACMSD Q8TDX5 2/20 0.36
SELL P14151 1/20 0.35
SELP P16109 1/20 0.35
GLA P06280 1/20 0.35
KEAP1 Q14145 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29975434 1.00 CES2 (0.45) CES2CES1KDM4EASPHKDM8
SCHEMBL31094955 0.84 CYP1A2 (0.44) CES2CES1KDM4EASPHKDM8
SCHEMBL7558115 0.83 CES2 (0.50) CES2CES1KDM4EASPHKDM8
SCHEMBL4851530 0.83 KDM4E (0.42) CES2CES1KDM4EASPHKDM8
SCHEMBL24717969 0.81 CYP1A2 (0.41) CES2CES1KDM4EASPHKDM8
SCHEMBL30827695 0.81 DGAT1 (0.55) CES2CES1KDM4EDGAT1MAP2K1
SCHEMBL28221635 0.81 ALDH1A1 (0.47) CES2CES1DGAT1SMN1; SMN2ALDH1A1
SCHEMBL241797 0.79 CES2 (0.70) CES2CES1KDM4EASPHKDM8
SCHEMBL31225023 0.79 KDM4E (0.40) KDM4EASPHKDM8CYP1A2TSHR
SCHEMBL1671271 0.79 KDM4E (0.40) KDM4EASPHKDM8CYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115073282-A Method for rapidly preparing 3-bromo-2, 4-difluorobenzoic acid based on microchannel continuous flow technology 都创(重庆)医药科技有限公司 2022-09-20 CN claimed
US-12581252-B2 Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors RELAY THERAPEUTICS, INC. (US) 2026-03-17 US disclosed
WO-2025108255-A1 POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海齐鲁制药研究中心有限公司 2025-05-30 WO disclosed
US-12219327-B2 Substituted isoindolines as PI3K-alpha inhibitors RELAY THERAPEUTICS, INC. (US) 2025-02-04 US disclosed
WO-2024240056-A1 SULFONAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF 深圳信立泰药业股份有限公司 2024-11-28 WO disclosed
US-20240287058-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2024-08-29 US disclosed
CN-118047736-A Synthesis method of 2,2', 6' -tetrafluoro- [1,1' -biphenyl ] compounds 广州佳途科技股份有限公司 2024-05-17 CN disclosed
CN-112543764-B Amide compound with BET proteolytic induction effect and medical application thereof 田边三菱制药株式会社 2024-05-10 CN disclosed
US-20230353959-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2023-11-02 US disclosed
US-20230348363-A1 COMPOUNDS AND THEIR USE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-11-02 US disclosed
CN-109438214-A The preparation method of the bromo- 2,4 difluorobenzene formic acid of high-purity 5- 大连奇凯医药科技有限公司 2019-03-08 CN disclosed
EP-2123644-B1 BENZOXAZEPINE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-12-17 EP disclosed
CN-104119332-A Benzo heterocyclic compounds as protein kinase inhibitors and preparation method and use thereof KECHOW PHARMA INC 2014-10-29 CN disclosed
WO-2014008214-A1 BIARYL-CONTAINING COMPOUNDS AS INVERSE AGONISTS OF ROR-GAMMA RECEPTORS BIOGEN IDEC MA INC. (US) 2014-01-09 WO disclosed
EP-2590968-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS Novartis AG (CH) 2013-05-15 EP disclosed
US-20130109682-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2013-05-02 US disclosed
US-8247403-B2 Benzoxazepine derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-21 US disclosed
WO-2012004217-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-12 WO disclosed
US-20100087418-A1 BENZOXAZEPINE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-04-08 US disclosed
EP-2123644-A1 BENZOXAZEPINE DERIVATIVES AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2009-11-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109682-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS PIM1, GSK3A, GSK3B CES2 1736/4885CES1 1720/4885KDM4E 636/4885
US-20230348363-A1 COMPOUNDS AND THEIR USE RXFP1, RXFP3, RXFP2 CES2 4134/4885CES1 1584/4885KDM4E 2832/4885
US-12219327-B2 Substituted isoindolines as PI3K-alpha inhibitors PIK3CD, PIK3CB, PIK3R1 CES2 1650/4885CES1 781/4885KDM4E 2705/4885
US-20100087418-A1 BENZOXAZEPINE DERIVATIVES AND USE THEREOF HTR2C, HTR5A, HTR2B CES2 939/4885CES1 894/4885KDM4E 985/4885
US-20240287058-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF PIK3CA, PIK3CB, PIK3CD CES2 1183/4885CES1 381/4885KDM4E 2924/4885
US-12581252-B2 Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors RORB, ROR1, RORA CES2 1588/4885CES1 366/4885KDM4E 3201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.